1353254-26-8

Basic information

• Product Name: tert-butyl N-[(3R)-1-phenylpiperidin-3-yl]carbamate
• Synonyms: tert-butyl N-[(3R)-1-phenylpiperidin-3-yl]carbamate
• CAS NO: 1353254-26-8
• Molecular Weight: 276.379
• Mol File: 1353254-26-8.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl N-[(3R)-1-phenylpiperidin-3-yl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-[(3R)-1-phenylpiperidin-3-yl]carbamate(1353254-26-8)
• EPA Substance Registry System: tert-butyl N-[(3R)-1-phenylpiperidin-3-yl]carbamate(1353254-26-8)

Safety Data

• Hazardous Substances Data: 1353254-26-8(Hazardous Substances Data)

Upstream product

• 309956-78-3 (R)-piperidin-3-ylcarbamic acid tert-butyl ester 
• 98-80-6 phenylboronic acid 

Relevant articles and documents

Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators

We previously reported diarylurea derivatives as cannabinoid type-1 receptor (CB1) allosteric modulators, which were effective in attenuating cocaine-seeking behavior. Herein, we extended the structure-activity relationships of PSNCBAM-1 (2) at the central phenyl ring directly connected to the urea moiety. Replacement with a thiophene ring led to 11 with improved or comparable potencies in calcium mobilization, [35S]GTPγS binding, and cAMP assays, whereas substitution with nonaromatic rings led to significant attenuation of the modulatory activity. These compounds had no inverse agonism in [35S]GTPγS binding, a characteristic that is often thought to contribute to adverse psychiatric effects. While 11 had good metabolic stability in rat liver microsomes, it showed modest solubility and blood-brain barrier permeability. Compound 11 showed an insignificant attenuation of cocaine seeking behavior in rats, most likely due to its limited CNS penetration, suggesting that pharmacokinetics and distribution play a role in translating the in vitro efficacy to in vivo behavior.

UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS

Heteroaryl and aliphatic analogs of diarylurea-based cannabinoid 1 receptor (CB1 R) allosteric modulators of formula (I) are described. Exemplary analogs can provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat

NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS

The present invention provides a compound of the Formula I:(Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.